Recent Study Explores Zika Virus Infections Industry Pipeline Review, 2017

Overview

Zika virus infection is caused by a virus transmitted primarily by Aedes mosquitoes. Zika virus is a member of the Flaviviridae family. Symptoms include fever, skin rashes, conjunctivitis, muscle and joint pain, malaise, and headache. Risk factors include being in tropical and subtropical areas. Zika virus can be transmitted through sexual intercourse. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications.

 Click here for sample report @ http://www.wiseguyreports.com/sample-request/2740062-zika-virus-infections-pipeline-review-h2-2017

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Zika Virus Infections - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Zika Virus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Zika Virus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Zika Virus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 9, 30, 25 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 9 and 5 molecules, respectively.

 Major Scope of the report:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Zika Virus Infections (Infectious Disease). 
- The pipeline guide reviews pipeline therapeutics for Zika Virus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. 
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. 
- The pipeline guide reviews key companies involved in Zika Virus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects. 

Table of Contents 

Table of Contents 2 
Introduction 5 
Zika Virus Infections - Overview 6 
Zika Virus Infections - Therapeutics Development 7 
Zika Virus Infections - Therapeutics Assessment 19 
Zika Virus Infections - Companies Involved in Therapeutics Development 27 
Zika Virus Infections - Drug Profiles 46 
Zika Virus Infections - Dormant Projects 160 
Zika Virus Infections - Discontinued Products 161 
Zika Virus Infections - Product Development Milestones 162 
Appendix 174

List of Tables 
Number of Products under Development for Zika Virus Infections, H2 2017 
Number of Products under Development by Companies, H2 2017 
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 

 .Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/2740062-zika-virus-infections-pipeline-review-h2-2017

Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. We also provide COTS (Commercial off the Shelf) business sector reports as custom exploration agreeing your particular needs.

WISEGUY RESEARCH CONSULTANTS PVT LTD
Office No. 528, Amanora Chambers
Pune - 411028
Maharashtra, India

This release was published on openPR.